司太立 20251222 摘要 斯太利是国内领先的碘造影剂供应商，拥有最大的产品规模和最齐全的 品种，碘海醇产能和产量位居国内前列，受益于国内碘造影剂市场从集 采影响中恢复，2024 年院端市场规模重回 150 亿元人民币水平。 公司已建成 2,400 余吨原料产能，其中 1,800 吨完成国内外质量体系认 证，预计年底提升至 3,000 吨，占全球需求近三分之一，前瞻性的产能 布局有望承接更多新需求，进一步提高市占率。 毛利改善受益于碘价下降、产能利用率提升及点回收技术，点回收已达 到原研水平，有效降低生产成本，提升盈利能力。 依托爱尔兰 IMAX 控股公司的注册优势和销售网络，公司积极推进制剂 国际化销售，截至 2024 年，IMAX 公司海外制剂销售额已达 8,620 万 元，协同效应显著。 上海斯泰利智能化改造项目已于 2025 年转固并投产，新增 1,200 万支 制剂产能，预计未来 3 至 4 年内，对内发货量将从 400 吨提升至 800 吨，实现翻倍增长。 Q&A 斯太利公司的业务情况及其国际化战略是什么？ 斯太利公司是一家专注于造影剂的 API（活性药物成分）和制剂一体化的企业， 成立于 1 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江司太立制药股份有限公司（以下简称"公司"）于 2025 年 6 月 12 日召 开第五届董事会第十六次会议审议通过《关于继续使用部分闲置募集资金暂时补 充流动资金的议案》，同意公司使用合计不超过 15,000.00 万元闲置募集资金暂 时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月且不超过募 投项目的实施期限。具体内容详见 2025 年 6 月 13 日公司于上海证券交易所网站 （www.sse.com.cn）披露的《关于继续使用部分闲置募集资金暂时补充流动资金 的公告》（公告编号：2025-032）。 证券代码：603520 证券简称：司太立 公告编号：2025-056 浙江司太立制药股份有限公司 关于暂时补充流动资金的募集资金全部归还至募集 资金专户的公告 截至本公告披露日，公司实际使用的闲置募集资金暂时补充流动资金 13,000.00 万元已全部归还至募集资金专户，并通知了保荐机构和保荐代表人。 特此公告。 浙江司太立制药股份有限公司董事会 2025年 ...

浙江司太立制药股份有限公司（以下简称"公司"）于 2025 年 6 月 12 日召 开第五届董事会第十六次会议审议通过《关于继续使用部分闲置募集资金暂时补 充流动资金的议案》，同意公司使用合计不超过 15,000.00 万元闲置募集资金暂 时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月且不超过募 投项目的实施期限。具体内容详见 2025 年 6 月 13 日公司于上海证券交易所网站 （www.sse.com.cn）披露的《关于继续使用部分闲置募集资金暂时补充流动资金 的公告》（公告编号：2025-032）。 证券代码：603520 证券简称：司太立 公告编号：2025-055 浙江司太立制药股份有限公司 关于部分暂时补充流动资金的募集资金归还至募集 资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至本公告披露日，该次募集资金暂时补充流动资金剩余 7,500 万元尚未归 还至募集资金专用账户。 特此公告。 截至本次归还日前，公司实际使用闲置募集资金暂时补充流动资金金额为 13,000.00 万 ...

Group 1 - The company has elected Mr. Zheng Fangwei as the employee director of the fifth board of directors, with a term starting from November 24, 2025 [1][3] - The election of the employee director complies with relevant laws and regulations, ensuring that the number of employee representatives does not exceed half of the total board members [1] Group 2 - The company's wholly-owned subsidiary, Shanghai Sitaili Pharmaceutical Co., Ltd., has received a drug registration certificate for Gadopentetate Dimeglumine Injection from the National Medical Products Administration [4][5] - The drug is classified as a Class 4 chemical drug and is primarily used for magnetic resonance imaging of various organs and tissues [5][7] - The total R&D investment for this drug has reached approximately 7.07 million yuan [6] - The market data indicates that the sales of Gadopentetate Dimeglumine Injection in Chinese public medical institutions are expected to exceed 700 million yuan in 2024 [8]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of Gadopentetic Acid Injection, indicating a significant milestone in its product development and regulatory compliance [1]. Group 1 - The company, Zhejiang Sitaili Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Shanghai Sitaili Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Gadopentetic Acid Injection [1].

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Group 1 - The core point of the article is that the company Sital (603520.SH) has received approval from the National Medical Products Administration for its gadopentetate dimeglumine injection, which is primarily used for magnetic resonance imaging of various organs and tissues in the human body [1] Group 2 - The approved drug is indicated for use in central nervous system imaging, including the brain and spinal cord, as well as abdominal, thoracic, pelvic, and limb imaging [1]

证券代码：603520 证券简称：司太立 公告编号：2025-054 浙江司太立制药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江司太立制药股份有限公司（以下简称"公司"）全资子公司上海司太立 制药有限公司（以下简称"上海司太立"）于近日收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的钆喷酸葡胺注射液《药品注册证书》，现将 具体情况公告如下： 本药品适应症：主要用于中枢神经（脑及脊髓）、腹、胸、盆腔、四肢等人 体脏器和组织的磁共振成像。 本药品的药品注册分类为化学药品 4 类。根据国家药监局《关于仿制药质量 和疗效一致性评价工作有关事项的公告》（2017 年第 100 号）文件相关规定， 本药品视为通过仿制药质量和疗效一致性评价。 截至目前，该药品累计研发投入共计约 707.67 万元。 三、药品市场情况 钆喷酸葡胺注射液经静脉注射进入体内后能改变局部组织的弛豫时间，增强 磁共振成像图像的清晰度和对比度。其适应症广泛、成像品质高、临床使用效果 好、不良反应发 ...

证券代码：603520 证券简称：司太立 公告编号：2025-053 浙江司太立制药股份有限公司 关于选举第五届董事会职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次选举职工董事工作完成后，公司第五届董事会中兼任公司高级管理 人员职务以及由职工代表担任的董事人数，合计未超过公司董事总数的二分 之一，符合有关法律法规、规范性文件及《公司章程》的规定。 特此公告。 浙江司太立制药股份有限公司董事会 2025 年 11 月 26 日 附： 根据《中华人民共和国公司法》（以下简称"《公司法》"）和修订后 的《公司章程》等有关规定，浙江司太立制药股份有限公司(以下简称"公司") 于近日召开职工代表大会，民主选举郑方卫先生（简历详见附件）为公司第 五届董事会职工董事，任期自选举之日（2025 年 11 月 24 日）至公司第五届 董事会任期届满为止。 郑方卫先生，男，1978 年出生，中国国籍，无境外永久居住权，本科学 历。2004 年至 2008 年任浙江司太立制药股份有限公司车间工艺员；2008 年 至 2016 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Gadobutrol Injection, which is primarily used for magnetic resonance imaging of various organs and tissues in the human body [1] Group 1 - The drug is indicated for use in central nervous system imaging, including the brain and spinal cord [1] - It is also applicable for imaging of abdominal, thoracic, pelvic, and limb organs and tissues [1]